nach oben

Erschienen in:

27.07.2022 | Research Letter

Influence of Darolutamide on Cabazitaxel Systemic Exposure

verfasst von: Stefan A. J. Buck, Niels A. D. Guchelaar, Peter de Bruijn, Inge M. Ghobadi Moghaddam-Helmantel, Esther Oomen-de Hoop, Hans M. Westgeest, Paul Hamberg, Danielle Mathijssen-van Stein, Martijn P. Lolkema, Stijn L. W. Koolen, Ronald de Wit, Ron H. J. Mathijssen

Erschienen in: Clinical Pharmacokinetics | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Excerpt

Patients with metastatic prostate cancer currently receive taxane chemotherapy or androgen receptor signalling inhibitors (ARSIs) already in the hormone-sensitive stage. Because of this extensive treatment history, patients with metastatic castration-resistant prostate cancer (mCRPC) are further prone to drug resistance as a result of cross-resistance and clonal evolution of therapy-resistant clones [1]. The taxane cabazitaxel, reserved for patients with mCRPC after progression on docetaxel, is often perceived as an option of last resort in this population. Therefore, strategies to overcome drug resistance to cabazitaxel are highly desired. …

Nur mit Berechtigung zugänglich

Buck SAJ, Koolen SLW, Mathijssen RHJ, de Wit R, van Soest RJ. Cross-resistance and drug sequence in prostate cancer. Drug Resist Updat. 2021;56: 100761. https://doi.org/10.1016/j.drup.2021.100761.CrossRefPubMed

Mout L, van Royen ME, de Ridder C, Stuurman D, van de Geer WS, Marques R, et al. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. EBioMedicine. 2021;5(73): 103681. https://doi.org/10.1016/j.ebiom.2021.103681.CrossRef

Belderbos BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, van der Meer N, de Bruijn P, et al. Influence of enzalutamide on cabazitaxel pharmacokinetics: a drug-drug interaction study in metastatic castration-resistant prostate cancer (mCRPC) patients. Clin Cancer Res. 2018;24(3):541–6. https://doi.org/10.1158/1078-0432.CCR-17-2336.CrossRefPubMed

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383(11):1040–9. https://doi.org/10.1056/NEJMoa2001342.CrossRefPubMed

Zurth C, Koskinen M, Fricke R, Prien O, Korjamo T, Graudenz K, et al. Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019;44(6):747–59. https://doi.org/10.1007/s13318-019-00577-5.CrossRefPubMedPubMedCentral

de Bruijn P, de Graan AJ, Nieuweboer A, Mathijssen RH, Lam MH, de Wit R, et al. Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding. J Pharm Biomed Anal. 2012;5(59):11–22. https://doi.org/10.1016/j.jpba.2011.10.010.CrossRef

Eisenberger M, Hardy-Bessard AC, Kim CS, Geczi L, Ford D, Mourey L, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m²) and the currently approved dose (25 mg/m²) in postdocetaxel patients with metastatic castration-resistant prostate cancer: PROSELICA. J Clin Oncol. 2017;35(28):3198–206. https://doi.org/10.1200/JCO.2016.72.1076.CrossRefPubMed

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–31. https://doi.org/10.1056/NEJMoa1903835.CrossRefPubMed

Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399(10336):1695–707. https://doi.org/10.1016/S0140-6736(22)00367-1.CrossRefPubMed

10.

Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2119115.CrossRefPubMedPubMedCentral

Titel: Influence of Darolutamide on Cabazitaxel Systemic Exposure
verfasst von: Stefan A. J. Buck
Niels A. D. Guchelaar
Peter de Bruijn
Inge M. Ghobadi Moghaddam-Helmantel
Esther Oomen-de Hoop
Hans M. Westgeest
Paul Hamberg
Danielle Mathijssen-van Stein
Martijn P. Lolkema
Stijn L. W. Koolen
Ronald de Wit
Ron H. J. Mathijssen
Publikationsdatum: 27.07.2022
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 10/2022
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-022-01159-6

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteer﻿s

Correction to: Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment

Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review

Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis

Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues

Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers